Targeting neurological abnormalities in lysosomal storage diseases

Raquel van Gool¹, Anthony Tucker-Bartley², Edward Yang³, Nicholas Todd⁴, Frank Guenther⁵, Benjamin Goodlett⁶, Walla Al-Hertani⁶, Olaf A Bodamer⁶, Jaymin Upadhyay⁷

Affiliations

¹ Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Faculty of Psychology and Neuroscience, Section Neuropsychology & Psychopharmacology, Maastricht University, Maastricht, The Netherlands.
² Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Department of Anesthesia, Critical Care and Pain Medicine, Harvard Medical School, Boston, MA, USA.
³ Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Department of Speech, Language and Hearing Sciences, Sargent College of Health and Rehabilitation Sciences, Boston University, Boston, MA, USA.
⁶ Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
⁷ Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, USA. Electronic address: jaymin.upadhyay@childrens.harvard.edu.

PMID: 34844772
DOI: 10.1016/j.tips.2021.11.005

Review

Targeting neurological abnormalities in lysosomal storage diseases

Raquel van Gool et al. Trends Pharmacol Sci. 2022 Jun.

. 2022 Jun;43(6):495-509.

doi: 10.1016/j.tips.2021.11.005. Epub 2021 Nov 27.

Authors

Raquel van Gool¹, Anthony Tucker-Bartley², Edward Yang³, Nicholas Todd⁴, Frank Guenther⁵, Benjamin Goodlett⁶, Walla Al-Hertani⁶, Olaf A Bodamer⁶, Jaymin Upadhyay⁷

Affiliations

¹ Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Faculty of Psychology and Neuroscience, Section Neuropsychology & Psychopharmacology, Maastricht University, Maastricht, The Netherlands.
² Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Department of Anesthesia, Critical Care and Pain Medicine, Harvard Medical School, Boston, MA, USA.
³ Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Department of Speech, Language and Hearing Sciences, Sargent College of Health and Rehabilitation Sciences, Boston University, Boston, MA, USA.
⁶ Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
⁷ Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, USA. Electronic address: jaymin.upadhyay@childrens.harvard.edu.

PMID: 34844772
DOI: 10.1016/j.tips.2021.11.005

Abstract

Central nervous system (CNS) abnormalities and corresponding neurological and psychiatric symptoms are frequently observed in lysosomal storage disorders (LSDs). The genetic background of individual LSDs is indeed unique to each illness. However, resulting defective lysosomal function within the CNS can transition normal cellular processes (i.e., autophagy) into aberrant mechanisms, facilitating overlapping downstream consequences including neurocircuitry dysfunction, neurodegeneration as well as sensory, motor, cognitive, and psychological symptoms. Here, the neurological and biobehavioral phenotypes of major classes of LSDs are discussed alongside therapeutic strategies in development that aim to tackle neuropathology among other disease elements. Finally, focused ultrasound blood-brain barrier opening is proposed to enhance therapeutic delivery thereby overcoming the key hurdle of central distribution of disease modifying therapies in LSDs.

Keywords: autophagy; central nervous system abnormalities; lysosomal storage disease; neurological symptoms; psychiatric symptoms.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Targeting neurological abnormalities in lysosomal storage diseases

Affiliations

Targeting neurological abnormalities in lysosomal storage diseases

Authors

Affiliations

Abstract

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources